Pearl Therapeutics ups its first round funding
Pearl Therapeutics, a biopharmaceutical company, has upped its first round of funding to $33.5 million after an additional $18 million investment, according to VentureWire.
New investor Nektar Therapeutics joins all of the company’s previous investors including Clarus Ventures, New Leaf Ventures and 5AM Ventures in this raise.
The Redwood City, Calif.-based Pearl Thera now has $36.4 million including debt funding.
Next Story: Interview with Vinod Dham, father of the Pentium, on a life in technology and venture investing
Previous Story: Should people in glass Facebook offices throw stones?
About the Author, MG Siegler
MG Siegler writes about technology trends and new media for VentureBeat, with a focus on mobile topics, social elements and key news stories. Before that, MG wrote about technology on his blog, ParisLemon. Originally from Ohio, MG attended the University of Michigan where he studied film. He's previously lived in Los Angeles where he worked in Hollywood and in San Diego where he did web development. He now lives in San Francisco.